房颤患者抗凝治疗的临床治疗有效性分析

Analysis of the Clinical Effectiveness of Anticoagulant Therapy in Patients with Atrial Fibrillation

目的分析房颤患者抗凝治疗的临床治疗有效性以及对于凝血指标的影响。方法研究对心内科的80例房颤患者进行了观察,患者在2018年6月—2020年2月期间入组,按照用药差异进行分组,分为对照组和观察组,对照组应用阿司匹林进行治疗,观察组联合抗凝治疗,对比两组的不良事件、病亡率、并发症和凝血指标。结果观察组病亡率为2.5%(1例),脑卒中和脑血栓发病率均为5.0%(2例),与对照组相比差异有统计学意义(χ^(2)=3.914、4.114、4.114,P<0.05);观察组患者并发症发生率为7.5%(3例),对照组为27.5%(11例),差异有统计学意义(χ^(2)=5.541,P<0.05);观察组患者凝血酶原时间为(13.6±2.4)s,纤维蛋白水平是(3.1±0.4)g/L,活化部分凝血酶原时间是(35.8±2.5)s,与对照组相比差异有统计学意义(t=2.401、4.939、9.995,P<0.05)。结论房颤患者实施抗凝治疗可以有效减少脑血管事件发生率和患者病亡率,并改善患者凝血指标,减少出血风险。

Objective To analyze the clinical effectiveness of anticoagulation therapy in patients with atrial fibrillation and its influence on coagulation indicators.Methods The study observed 80 patients with atrial fibrillation in the Department of Cardiology.The patients were enrolled from June 2018 to February 2020 and were grouped according to the difference in medication as the control group and the observation group.The control group was treated with aspirin,and the observation group was combined with anticoagulation therapy.To compare the adverse events,mortality rate,complications and coagulation indicators of the two groups.Results The mortality rate of the observation group was 2.5%(1 case),and the incidence of stroke and cerebral thrombosis were both 5.0%(2 cases).Compared with the control group,the difference was statistically significant(χ^(2)=3.914,4.114,4.114,P<0.05);the incidence of complications in the observation group was 7.5%(3 cases),and the control group was 27.5%(11 cases),the difference was statistically significant(χ^(2)=5.541,P<0.05);the prothrombin time in the observation group It was(13.6±2.4)s,the fibrin level was(3.1±0.4)g/L,and the activated partial prothrombin time was(35.8±2.5)s.Compared with the control group,the difference was statistically significant(t=2.401,4.939,9.995,P<0.05).Conclusion Anticoagulant therapy for patients with atrial fibrillation can effectively reduce the incidence of cerebrovascular events and patient mortality,improve the coagulation indicators of patients,and reduce the risk of bleeding.